Cue Biopharma reports Q4 EPS (37c) vs (26c) last year

Reports Q4 revenue $151,000 vs $8.254M last year. "2022 was a strategically important and significant year for Cue Biopharma with the emergence of positive clinical data from our ongoing trials with CUE-101 – our lead oncology drug product candidate from the CUE-100 series – validating and derisking our Immuno-STAT(TM) platform, and having accessed opportunities to secure a strong financial position that enable us to further execute on our corporate and clinical goals throughout 2023 and well into 2024," said Daniel Passeri, chief executive officer of Cue Biopharma. "Importantly, we plan to present updated clinical data from our representative programs from the CUE-100 series oncology programs at an upcoming scientific conference with the aim of further demonstrating the potential significance of our platform and clinical development approach for the treatment of multiple cancers. Additionally, we look forward to advancing our lead autoimmune disease asset, CUE-401, toward the clinic through our recent partnership with Ono Pharmaceutical and will continue to seek similar partnerships that support building out our promising pipeline of potential breakthrough therapeutics."